Compare RGP & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGP | MOLN |
|---|---|---|
| Founded | 1996 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Business Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.0M | 144.0M |
| IPO Year | 2000 | 2021 |
| Metric | RGP | MOLN |
|---|---|---|
| Price | $4.49 | $3.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $7.00 | ★ $8.38 |
| AVG Volume (30 Days) | ★ 259.7K | 2.2K |
| Earning Date | 04-08-2026 | 05-12-2026 |
| Dividend Yield | ★ 6.85% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $551,331,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $374.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.06 | $3.41 |
| 52 Week High | $6.07 | $5.36 |
| Indicator | RGP | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 64.72 | 45.28 |
| Support Level | $4.22 | $3.52 |
| Resistance Level | $4.52 | $4.51 |
| Average True Range (ATR) | 0.18 | 0.13 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 82.28 | 38.37 |
Resources Connection Inc provides consulting and business initiative support services predominantly through its operative subsidiary, Resources Global Professionals. It has two segments RGP ( Resources Global Professionals.) and Sitrick. The RGP segment is focused on delivering consulting services catering to its client's operational needs and change initiatives utilizing a combination of bench and on-demand, talent. The Sitrick segment provides corporate, financial, transactional, and crisis communication and management services. The company generates a majority of its revenue from the RGP segment. Geographically, it derives its key revenue from North America and the rest from Europe and the Asia Pacific region.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.